Oncology drug pricing: potential Medicare savings on cancer-directed and supportive care medications through the Mark Cuban cost plus drug model
The Oncologist · 2024
DOI: 10.1093/oncolo/oyae083 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Max J Bouvette und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United Ststes. Hauptthemen laut MEDLINE: Prescription Drugs, Antineoplastic Agents, Neoplasms, Medicare Part D. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prescription drug costs within oncology remain a challenge for many patients with cancer. The Mark Cuban Cost Plus Drug Company (MCCPDC) launched in 2022, aiming to provide transparently priced medications at reduced costs. In this study, we sought to describe the potential impact of MCCPDC on Medicare Part-D oncology spending related to cancer-directed (n = 7) and supportive care (n = 26) drugs. We extracted data for drug-specific Part-D claims and spending for 2021. Using 90-count purchases from MCCPDC, we found potential Part-D savings of $857.8 million (91% savings) across the 7 cancer-directed drugs and $28.7 million (67% savings) across 21/26 (5/26 did not demonstrate savings) supportive care drugs. Collectively, our findings support that alternative purchasing models like MCCPDC may promote substantial health care savings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United Ststes.
- Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
- Section of Hematology/Oncology, Department of Medicine, Stephenson Cancer Center and the University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
ORCID-Profile: Max J Bouvette
Zitieren
APA
Bouvette, M. J., Lam, A. B., Bouvette, C., Ayanambakkam, A., & Nipp, R. D. (2024). Oncology drug pricing: potential Medicare savings on cancer-directed and supportive care medications through the Mark Cuban cost plus drug model. The Oncologist. https://doi.org/10.1093/oncolo/oyae083
Vancouver
Bouvette MJ, Lam AB, Bouvette C, Ayanambakkam A, Nipp RD. Oncology drug pricing: potential Medicare savings on cancer-directed and supportive care medications through the Mark Cuban cost plus drug model. The Oncologist. 2024. doi:10.1093/oncolo/oyae083
BibTeX
@article{Bouvette2024,
author = {Bouvette, Max J and Lam, Anh B and Bouvette, Christopher and Ayanambakkam, Adanma and Nipp, Ryan D},
title = {Oncology drug pricing: potential Medicare savings on cancer-directed and supportive care medications through the Mark Cuban cost plus drug model},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyae083}
}
EUVIMED